<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Schizophrenia in adults: Epidemiology and pathogenesis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Schizophrenia in adults: Epidemiology and pathogenesis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Schizophrenia in adults: Epidemiology and pathogenesis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard A Fischer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert W Buchanan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H31673341"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Schizophrenia is among the most disabling and economically catastrophic medical disorders. It is ranked by the World Health Organization as one of the top 10 illnesses contributing to the global burden of disease [<a href="#rid1">1</a>].</p><p>Characteristics of schizophrenia typically include positive symptoms, such as hallucinations and delusions; disorganized behavior; negative symptoms, such as anhedonia, lack of motivation, flat affect, and poverty of speech; and impairments in cognition, including attention, memory, and executive functions. The illness is commonly associated with impairments in social and occupational functioning [<a href="#rid2">2</a>]. Antipsychotic medications are the first-line treatment for schizophrenia. Evidence-based psychosocial interventions in conjunction with pharmacotherapy can help patients achieve recovery.</p><p>This topic discusses the epidemiology and pathogenesis of schizophrenia. Clinical manifestations, assessment, diagnosis, and course of schizophrenia are discussed separately. Anxiety and depression in schizophrenia are discussed separately. Psychosocial and pharmacologic treatments for schizophrenia are discussed separately, including long-acting antipsychotics, <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, and management of antipsychotic side effects. Evaluation and management of treatment resistant schizophrenia are also reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15250.html" rel="external">"Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15774.html" rel="external">"Schizophrenia in adults: Psychosocial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14791.html" rel="external">"Depression in schizophrenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15259.html" rel="external">"Anxiety in schizophrenia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14808.html" rel="external">"Evaluation and management of treatment-resistant schizophrenia"</a>.)</p><p></p><p class="headingAnchor" id="H31673348"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Schizophrenia occurs throughout the world. The prevalence of schizophrenia (ie, the number of cases in a population at any one time point) approaches 1 percent internationally. The incidence (the number of new cases annually) is approximately 1.5 per 10,000 people [<a href="#rid3">3</a>]. Age of onset is typically during adolescence; childhood and late-life onset (over 45 years) are less common. Slightly more men are diagnosed with schizophrenia than women (on the order of 1.4:1) [<a href="#rid4">4</a>], and women tend to be diagnosed later in life than men. Modal age of onset is between 18 and 25 for men and between 25 and 35 for women, with a second peak occurring around menopause [<a href="#rid5">5</a>]. There is also some indication that the prognosis is worse in men [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H31673355"><span class="h2">Co-occurring conditions</span><span class="headingEndMark"> — </span>People with schizophrenia have higher rates of several psychiatric disorders than people without schizophrenia, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Depressive disorders (see  <a class="medical medical_review" href="/z/d/html/14791.html" rel="external">"Depression in schizophrenia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety disorders: social anxiety disorder, posttraumatic stress disorder, and obsessive-compulsive disorder (see  <a class="medical medical_review" href="/z/d/html/15259.html" rel="external">"Anxiety in schizophrenia"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol and other substance use disorders (see  <a class="medical medical_review" href="/z/d/html/7798.html" rel="external">"Co-occurring schizophrenia and substance use disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment and diagnosis"</a>)</p><p></p><p>People with schizophrenia are also at greater risk for co-occurring conditions, such as metabolic and neurologic problems. (See  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis", section on 'Associated physical manifestations'</a>.)</p><p class="headingAnchor" id="H5381131"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>A number of epidemiological risk factors have been associated with the development of schizophrenia [<a href="#rid8">8</a>], including:</p><p class="bulletIndent1"><span class="glyph">●</span>Living in an urban area [<a href="#rid9">9,10</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immigration [<a href="#rid11">11,12</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obstetrical complications [<a href="#rid13">13</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late winter-early spring birth – Perhaps reflecting exposure to influenza virus during neural development</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advanced paternal age at conception [<a href="#rid14">14</a>] – May be associated with an increased risk of de novo mutations [<a href="#rid15">15</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cannabis use and cigarette smoking [<a href="#rid16">16,17</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Childhood adversity [<a href="#rid18">18</a>]</p><p></p><p>Environmental risk factors for schizophrenia are discussed below. (See <a class="local">'External factors'</a> below.)</p><p class="headingAnchor" id="H31673362"><span class="h2">Cost</span><span class="headingEndMark"> — </span>The cost of schizophrenia is staggering. The overall cost of schizophrenia in the United States in 2002 was estimated at approximately $63 billion [<a href="#rid19">19</a>]. This figure includes direct health care costs and indirect costs associated with loss of productivity. A study comparing the cost of schizophrenia in India in 2001 with the cost in the same catchment area in 2011 found that the cost had doubled in those 10 years, mainly related to increases in indirect costs [<a href="#rid20">20</a>]. A study examining United States insurance claims found that the annual health-related expenses of someone with chronic schizophrenia averaged more than $15,000 [<a href="#rid21">21</a>]. The cost of schizophrenia treatment from 2004 to 2009 to Medicare in the United States increased from $9.4 billion to $11.5 billion [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H296339"><span class="h2">Deficit schizophrenia</span><span class="headingEndMark"> — </span>Deficit schizophrenia, characterized by primary, enduring negative symptoms, seems to be a specific disease process within the larger syndrome of schizophrenia. Approximately 15 to 20 percent of the total schizophrenia population has the deficit form of schizophrenia [<a href="#rid23">23-26</a>]. They are more likely to be male and more likely to have relatives with schizophrenia than people with nondeficit schizophrenia [<a href="#rid27">27-31</a>]. As opposed to the excess of late winter-early spring births observed in schizophrenia in general, there is a disproportionate rate of summer births in the deficit group [<a href="#rid23">23,32</a>]. Examples of negative symptoms include anhedonia, asociality, blunted affect, lack of motivation, and poverty of speech. People with deficit schizophrenia are less likely to have co-occurring substance misuse disorders, depression, suicidal ideation and behavior, or delusions with high emotional content (such as jealous delusions) compared to nondeficit schizophrenia [<a href="#rid33">33-35</a>]. (See  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis", section on 'Negative symptoms'</a>.)</p><p class="headingAnchor" id="H31673369"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Although the pathogenesis of the disorder is unknown, it is almost certain that schizophrenia represents a syndrome comprised of multiple diseases that present with similar signs and symptoms [<a href="#rid36">36</a>]. This heterogeneity complicates the elucidation of the etiological and pathophysiological factors that underlie the group of disorders. In addition, schizophrenia appears to be a uniquely human condition, which limits the utility of animal models and further complicates the elucidation of the etiopathophysiology of the disorder [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H3493204418"><span class="h2">Genetic and external factors</span><span class="headingEndMark"> — </span>There is considerable evidence to suggest that the pathophysiology of schizophrenia proceeds from a complex interaction between genes and the environment, which complicates efforts to differentiate the relative contributions of genetic from environmental risk factors. For example, environmental factors can influence gene expression just as a person’s genetic make-up can influence response to environmental stressors.</p><p>The result of the interplay between genetic and external risk factors is disruption of neural circuit and neurotransmitter system function. (See <a class="local">'Neurodevelopment, neuropathology, and vulnerabilities'</a> below and <a class="local">'Neurotransmitters'</a> below.)</p><p class="headingAnchor" id="H31673376"><span class="h3">Genetic factors</span><span class="headingEndMark"> — </span>Twin studies were the first studies to provide compelling evidence for the role of genetic factors in the etiology of schizophrenia. These studies were conducted in monozygotic and dizygotic twins to examine the concordance rates of schizophrenia within the twin pairs. The observed concordance rate in monozygotic twins, who share 100 percent of their genes, is approximately 40 to 50 percent, whereas the observed concordance rate in dizygotic twins, who share 50 percent of their genes, is approximately 10 to 15 percent. [<a href="#rid37">37-39</a>]. The increased concordance rate of schizophrenia in monozygotic compared to dizygotic twins suggests a strong genetic component to schizophrenia. The offspring of the unaffected monozygotic twins are at increased risk of schizophrenia, which further supports the existence of a genetic predisposition for the illness. The fact that the monozygotic twin concordance rate is less than 100 percent, however, suggests that nongenetic, environmental factors are also involved in the development of the illness [<a href="#rid37">37-39</a>]. Adoption studies have provided further evidence for the presence of genetic risk factors.</p><p>Although there is abundant evidence for genetic risk factors, the specific genes involved in the etiology of schizophrenia have not been identified. Initial studies have used genetic linkage or candidate gene approaches to identify several specific genes as candidates for a role in the development of schizophrenia  (<a class="graphic graphic_table graphicRef69865" href="/z/d/graphic/69865.html" rel="external">table 1</a>).</p><p>The mapping of the human genome has allowed for the study of associations between gene variants and risk or occurrence of diseases, ie, genome-wide association studies (GWAS). The results of GWAS of schizophrenia support a polygenic model, in which multiple genes with additive small effects lead to the disorder. As many as 500,000 single nucleotide polymorphisms (SNPs) have been tested in GWAS for association with schizophrenia. In a study of over 35,000 cases and 110,000 controls, 108 SNPs were found to have a significant association with schizophrenia [<a href="#rid40">40</a>]. The identified genetic loci supported the involvement of the dopaminergic and glutamatergic neurotransmitter systems in the pathophysiology of schizophrenia. The study also replicated previous studies that have shown an association between genes of the major histocompatibility complex (MHC), which support immune functions, and schizophrenia. A 2016 study of the MHC locus demonstrated that expression of complement component 4 allele A (C4A) was proportional to the risk of having schizophrenia [<a href="#rid41">41</a>]. C4 expression and activity were then tested in mouse models and shown to be related to adolescent pruning of brain synapses. These findings are consistent with decreased “neuropil,” or dendritic density, which has been reliably observed in people with schizophrenia [<a href="#rid42">42</a>]. In the largest GWAS of schizophrenia (76,755 cases and 243,649 controls), 287 SNPs were found to have a significant association with schizophrenia, with multiple SNPs related to genes that are implicated in synaptic biology [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/2902.html" rel="external">"Genetic association and GWAS studies: Principles and applications"</a>.)</p><p>Another attempt to delineate the genetics of schizophrenia is the evaluation of copy number variants (CNVs), which are genes that have been duplicated or deleted. People with schizophrenia have been found to have higher rates of CNVs. The most frequent CNV associated with schizophrenia is a deletion on the long arm of chromosome 22 (22q11) [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/2902.html" rel="external">"Genetic association and GWAS studies: Principles and applications"</a>.)</p><p>Finally, there has been considerable interest in the potential role that epigenetics may play in the etiology of schizophrenia [<a href="#rid45">45</a>]. Epigenetics refers to the chemical modification of DNA and histones, the proteins that are involved in the packaging of DNA in the nucleus. These epigenetic modifications are of particular interest in schizophrenia, since they provide a mechanism for the translation of environmental risk factors into altered gene function. There have been several small sample studies conducted in people with a first episode of psychosis [<a href="#rid46">46</a>]. These studies provide evidence for epigenetic alterations in schizophrenia, but they have not been able to demonstrate a consistent set of abnormalities [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H3353206397"><span class="h3">External factors</span></p><p class="headingAnchor" id="H31673390"><span class="h4">Obstetrical complications</span><span class="headingEndMark"> — </span>Various perinatal problems, grouped together for analysis as “obstetrical complications,” increase the risk of later development of schizophrenia two-fold [<a href="#rid13">13</a>]. These perinatal problems include:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemorrhage</p><p class="bulletIndent1"><span class="glyph">●</span>Preterm labor</p><p class="bulletIndent1"><span class="glyph">●</span>Blood-group incompatibilities</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal hypoxia </p><p class="bulletIndent1"><span class="glyph">●</span>Maternal infection (see <a class="local">'Infections'</a> below)</p><p></p><p>The accuracy of these data, based on maternal recall many years after childbirth, has been questioned, but studies suggest that the risk does not appear to be influenced by inaccurate memories [<a href="#rid47">47,48</a>]. The association between obstetrical complications and the development of schizophrenia has also been observed in data from medical records, which do not rely on recall [<a href="#rid13">13</a>]. The presence of obstetrical complications may interact with genetic risk for the illness, such that the liability for schizophrenia explained by genetic factors is significantly greater in the offspring of women who had perinatal complications, than those who did not [<a href="#rid49">49</a>].</p><p>In studies based on subsequent hospital records, pregnancy during famines in the Netherlands (1944 through 1945) [<a href="#rid50">50</a>] and in China (1959 through 1961) [<a href="#rid51">51,52</a>] has been associated with a two-fold risk of schizophrenia in the offspring. The results of these studies indicate that maternal nutrition is a critical factor in the development of schizophrenia. Other, related factors associated with an increased risk of subsequently developing schizophrenia include being the product of an unwanted pregnancy [<a href="#rid53">53</a>] and the prenatal death of the father [<a href="#rid54">54</a>].</p><p>Increased prenatal maternal stress has been proposed as the common pathophysiological mechanism underlying risk factors, such as famine, bereavement, and antenatal infection. An animal model provides some support for this theory [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H31673397"><span class="h4">Infections</span><span class="headingEndMark"> — </span>Several epidemiological findings have suggested a possible role of certain infectious agents as potential risk factors for the development of schizophrenia:</p><p class="bulletIndent1"><span class="glyph">●</span>Numerous epidemiological studies have found an increase in schizophrenia prevalence in cohorts born during influenza epidemics [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The increased risk for schizophrenia among those born in the late winter-early spring could possibly reflect increased maternal exposure to influenza virus during prenatal neural development.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High maternal IgG antibodies to the parasite toxoplasma gondii have been found to increase the relative risk of developing schizophrenia in offspring by approximately 60 to 70 percent [<a href="#rid57">57,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies have varied on whether herpes simplex virus type 2 maternal infection increases the risk for schizophrenia; some studies have found increased risks between 60 percent to more than 400 percent [<a href="#rid59">59,60</a>], while other studies have found no increased risk [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other infectious agents associated with schizophrenia appear to have an influence outside the model of perinatal exposure of the affected individual. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher maternal levels of IgG to toxoplasma gondii are related to the later development of schizophrenia in the mother herself [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measles antibodies are higher in people with schizophrenia, especially in those with recent-onset of psychosis, than controls [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bacterial infections during childhood, which lead to hospitalization, are related to an increased risk for developing schizophrenia [<a href="#rid64">64,65</a>].</p><p></p><p>The mechanism by which infections increase the risk of schizophrenia is unclear. There is little evidence to suggest that the risk is associated with direct damage by the infectious agent to the central nervous system (CNS). A study comparing individuals hospitalized for meningitis as children to a control group who were hospitalized with gastroenteritis as children found no difference in the risk of later hospitalization for schizophrenia [<a href="#rid66">66</a>]. A more likely explanation is that infection by certain agents triggers an immune response in a mother that is passed through the placenta to the developing fetus, which compromises the blood brain barrier and allows antibodies, which cross-react with CNS proteins, to enter into the developing nervous system [<a href="#rid67">67</a>]. Early childhood infections could also initiate an immune response and lead to a general state of increased inflammation. (See <a class="local">'Inflammation'</a> below.)</p><p class="headingAnchor" id="H31673404"><span class="h4">Inflammation</span><span class="headingEndMark"> — </span>Increased immune system activation leads to higher levels of circulating pro-inflammatory cytokines. Increased pro-inflammatory cytokine levels have been frequently observed in schizophrenia [<a href="#rid68">68</a>]. Cytokines can alter the blood-brain barrier, or be produced locally in the CNS by activated microglia, and may be responsible for psychosis, its exacerbation, or cognitive impairments [<a href="#rid69">69</a>]. The actions of antipsychotic drugs may be partially mediated by the anti-inflammatory effects of these agents [<a href="#rid70">70</a>].</p><p>In addition to associations between schizophrenia and some infections, there is other evidence for abnormal immune activation in people with schizophrenia. (See <a class="local">'Infections'</a> above.)</p><p>Autoimmune disorders that have been associated with a higher prevalence of schizophrenia include [<a href="#rid71">71,72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acquired hemolytic anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Bullous pemphigoid</p><p class="bulletIndent1"><span class="glyph">●</span>Celiac disease</p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial cystitis</p><p class="bulletIndent1"><span class="glyph">●</span>Thyrotoxicosis</p><p></p><p>(A notable exception is rheumatoid arthritis, in which schizophrenia rates are lower than expected based on rates in the general population [<a href="#rid73">73</a>]. People with schizophrenia are also more likely to have circulating antibodies to proteins common in most Western diets, such as gluten [<a href="#rid74">74,75</a>] and casein [<a href="#rid76">76,77</a>].)</p><p>Clinical trials of anti-inflammatory agents for psychosis have been spurred, in part, by these findings.</p><p>Inflammation in people with schizophrenia may also be responsible for some of the disorder’s associated conditions such as heart disease (through decreased elasticity of inflamed blood vessels) and diabetes (See  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis", section on 'Metabolic disturbances'</a>.)</p><p class="headingAnchor" id="H15986866"><span class="h4">Cannabis use</span><span class="headingEndMark"> — </span>Epidemiological studies suggest that cannabis use is a risk factor for the development of psychosis [<a href="#rid78">78-86</a>]. The increased risk posed by cannabis use depends on other risk factors, such as family history. In contrast to the psychotomimetic properties of delta-9-tetrahydrocannabinol (THC), the cannabis ingredient cannabidiol (CBD) has been shown to attenuate psychotic symptoms [<a href="#rid87">87,88</a>]. The mechanism by which CBD exerts this potential effect is unknown. (See  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects", section on 'Psychiatric effects'</a>.)</p><p class="headingAnchor" id="H2971470202"><span class="h4">Cigarette smoking</span><span class="headingEndMark"> — </span>Cigarette smoking has been associated with schizophrenia. Smoking may confer a risk of developing schizophrenia or there may be a common, underlying risk factor for both the development of schizophrenia and smoking. In a prospective study including over 900,000 individuals, the incidence of newly diagnosed schizophrenia (or nonaffective psychosis) was higher in smokers than in nonsmokers (adjusted incidence rate ratio 3.32, 95% CI 2.67-4.14 in males and 2.13, 95% CI 1.76-2.57 in females) [<a href="#rid89">89</a>]. The risk was found to be dose dependent, with individuals identifying as heavy smokers at greater risk of diagnosis with schizophrenia than those identifying as moderate or light smokers.</p><p>Studies of the effect of cigarette smoking during pregnancy on the risk for the development of schizophrenia have been mixed. The first study to use serum cotinine as a biomarker for smoking, however, found cigarette smoking during pregnancy significantly increases the odds of schizophrenia in the offspring (odds ratio 3.41, 95% CI 1.86-6.24). This study was based on a Finnish national health registry and included 977 cases of schizophrenia [<a href="#rid90">90</a>].</p><p>Although this finding could be related to nicotinic acetylcholine perturbations during development or fetal hypoxia, it may simply reflect genetic risk. It is well known that first-degree relatives of people with schizophrenia have higher rates of smoking compared with the relatives of healthy controls [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H31673411"><span class="h4">Immigration</span><span class="headingEndMark"> — </span>Numerous studies in multiple countries have observed a higher prevalence of schizophrenia in immigrant populations compared with native-born populations [<a href="#rid11">11,12</a>]. This increased relative risk can be as high as four-fold, depending on the study. An increased risk appears to extend to second-generation immigrants as well [<a href="#rid12">12</a>].</p><p>Several possible explanations for the association between immigrants and schizophrenia have been proposed:</p><p class="bulletIndent1"><span class="glyph">●</span>Schizophrenia may be overdiagnosed in immigrant populations; however, further research suggests that this cannot entirely explain the increase in risk observed [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In people with either a genetic or neurodevelopmental biological risk for schizophrenia, stress can play a role in the ultimate development of the disorder. In this way, the stress of immigration, becoming part of an outsider group, may contribute to the development of schizophrenia. Studies have found associations between the amount of social discrimination experienced by immigrant groups and the rates of schizophrenia in the group; that is, immigrant groups experiencing more discrimination have higher rates of schizophrenia than immigrant groups experiencing lower rates of social discrimination. This finding has been observed in several immigrant groups in several countries:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ethiopian immigrants to Israel [<a href="#rid93">93</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Moroccan immigrants to the Netherlands [<a href="#rid12">12</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Caribbean immigrants to the United Kingdom [<a href="#rid94">94</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The increased risk of schizophrenia in immigrants may be related to vitamin D deficiency, especially among individuals who move to more northern latitudes [<a href="#rid95">95</a>].</p><p></p><p class="headingAnchor" id="H2379505840"><span class="h4">Childhood adversity</span><span class="headingEndMark"> — </span>Childhood adversity includes physical, psychological or sexual abuse and parental separation [<a href="#rid8">8</a>]. In a meta-analysis of 36 cross-sectional and prospective studies, childhood adversities were found to be significantly related to the occurrence of positive psychotic symptoms or a mental illness with psychosis, including schizophrenia (odds ratio 2.8). The estimated population attributable risk was 33 percent [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H2544083698"><span class="h2">Neurodevelopment, neuropathology, and vulnerabilities</span><span class="headingEndMark"> — </span>Schizophrenia is a neurodevelopmental disorder with neuropathological changes that may begin in utero [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H2286452221"><span class="h3">Brain morphology and neuropathology</span><span class="headingEndMark"> — </span>Studies including people with prodromal symptoms or a first episode of psychosis have shown reductions in gray matter volumes in multiple brain regions, including prefrontal, and superior and medial temporal lobes [<a href="#rid97">97</a>]. The neuroanatomical changes in the early stages of psychosis appear beyond those associated with normal development [<a href="#rid98">98</a>].</p><p>Increasing evidence suggests that the neuropathological changes in the prodrome and first episode of psychosis are dynamic and may differ from what is observed in the more chronic forms of the illness. This neuroplasticity in early psychosis may offer a window of opportunity to alter the course of the illness.</p><p class="headingAnchor" id="H2288855303"><span class="h3">Vulnerability to insults</span><span class="headingEndMark"> — </span>Pre- or perinatal neurodevelopmental abnormalities are likely to lead to a vulnerability to postpubertal insults that contribute to the accelerated loss of gray matter and aberrant connectivity in the cortical regions of vulnerable individuals. Additionally, external factors, such as substance use, stress, and maternal infection, may contribute to the pathophysiological process(es) [<a href="#rid98">98-100</a>]. (See <a class="local">'External factors'</a> above.)</p><p>While disturbances of neurodevelopment early in life may be necessary for the future emergence of the illness, environmental influences during the late adolescent period may contribute to the emergence of a first episode of psychosis via a range of possible interconnected neuropathological mechanisms. Examples of this include: increased hypothalamic pituitary axis activity, N-methyl-D-aspartate receptor hypofunction, glutamatergic or dopaminergic transmission abnormalities, reduced neuroplasticity, and neuroinflammation [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H2123337607"><span class="h3">Hypofrontality/brain glucose metabolism</span><span class="headingEndMark"> — </span>Decreased glucose metabolism, particularly in the frontal cortex, may be a contributing factor to the pathophysiology of schizophrenia. Hypofrontality is theorized to be related to the negative and cognitive symptoms that are pervasive and often refractory to treatment in schizophrenia. In a meta-analysis of 36 studies including 1335 participants, regional brain glucose metabolism in participants with schizophrenia were compared to healthy controls [<a href="#rid102">102</a>]. Frontal absolute glucose metabolism and metabolism relative to whole brain were lower in participants with chronic schizophrenia than controls or those with first episode of psychosis, with differences most pronounced in the medicated participants with schizophrenia. Differences were not found in parietal, temporal, occipital lobe, or thalamic metabolism in participants with schizophrenia versus controls. Although this meta-analysis could not determine whether the decreased glucose metabolism observed in the frontal cortex of people with schizophrenia is a result of chronic illness, a cause of chronic illness, or whether it is related to medication exposure, it supports a relationship between hypofrontality and schizophrenia.</p><p class="headingAnchor" id="H3825906927"><span class="h2">Neurotransmitters</span></p><p class="headingAnchor" id="H31673425"><span class="h3">Dopamine</span><span class="headingEndMark"> — </span>The vast majority of drugs with antipsychotic properties block the dopaminergic D2 receptor, a finding that has led to the dopamine hypothesis of schizophrenia, in which excess dopamine in the mesolimbic tract has been hypothesized to cause positive psychotic symptoms. The mechanisms that underlie this alteration in dopamine activity has been the focus of considerable study. Research suggests that decreased activity of the presynaptic D2 autoreceptor may represent the underlying cause of the excess mesolimbic dopamine [<a href="#rid103">103</a>].</p><p>However, if dopamine were the sole neurotransmitter disrupted in schizophrenia, then antipsychotics would be universally and completely effective for these symptoms, but, despite adequate antipsychotic treatment, many people with schizophrenia continue to exhibit positive symptoms. Therefore, it is likely that dysfunction in other neurotransmitter systems is required to explain why many people with the illness exhibit only a partial reduction in positive symptoms, and why <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, the most efficacious antipsychotic in schizophrenia, is a weak D2 antagonist.</p><p>Decreased dopamine in the prefrontal cortex (largely affecting the D1 receptor) may be responsible for some of the cognitive and negative symptoms observed in schizophrenia [<a href="#rid104">104,105</a>]. (See  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H31673432"><span class="h3">Glutamate</span><span class="headingEndMark"> — </span>Glutamate is the major CNS excitatory neurotransmitter. Hypofunction of the N-methyl-D-aspartate (NMDA) glutamate receptor has been hypothesized to contribute to the pathology of schizophrenia [<a href="#rid106">106</a>]. Evidence comes from:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical observations of people who have misused phencyclidine (a NMDA receptor antagonist)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Challenge studies using <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> (a NMDA receptor antagonist) [<a href="#rid107">107-109</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic findings [<a href="#rid106">106</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postmortem studies [<a href="#rid110">110</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies measuring the levels of endogenous NMDA receptor agonists and antagonists in the CNS of people with schizophrenia [<a href="#rid111">111-113</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Magnetic resonance spectroscopy studies [<a href="#rid114">114</a>]</p><p></p><p>Clinical trials with agents that enhance glutamatergic neurotransmission have had varied results depending on the mechanism of the agent used [<a href="#rid115">115,116</a>]. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p class="headingAnchor" id="H31673439"><span class="h3">Gamma-amino-butyric acid</span><span class="headingEndMark"> — </span>Gamma-aminobutyric acid (GABA) is the major CNS inhibitory neurotransmitter. GABAergic interneurons are important for regulation of prefrontal cortical function, through their modulation of glutamatergic pyramidal cells. Several lines of evidence suggest that these interneurons are dysfunctional in people with schizophrenia [<a href="#rid113">113,117-122</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Postmortem studies in people with schizophrenia have found decreased levels of glutamic acid decarboxylase (GAD67) mRNA expression in the prefrontal cortex [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In people with schizophrenia with decreased GAD67, there is a decrease in the density of chandelier cell connections with the pyramidal cell axon initial segment [<a href="#rid123">123</a>] and in the immunoreactivity of the GABA plasma membrane transporter-1 in chandelier cell axon terminals [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There appears to be a decrease in GABA reuptake transporter mRNA levels [<a href="#rid123">123</a>] and an increase in GABAA alpha-2 subunit density on the axon initial segment [<a href="#rid123">123</a>], both of which may be compensatory shifts.</p><p></p><p class="headingAnchor" id="H31673446"><span class="h3">Acetylcholine</span><span class="headingEndMark"> — </span>The observation of increased smoking behaviors in people with schizophrenia [<a href="#rid124">124-127</a>] led to the hypothesis that nicotine, which stimulates a subset of acetylcholine receptors, is correcting a fundamental neurochemical problem in schizophrenia. Treatment with nicotine or a nicotinic cholinergic drug can normalize some eye-tracking and EEG abnormalities observed in people with schizophrenia [<a href="#rid128">128-132</a>] and may acutely improve some aspects of cognition [<a href="#rid133">133,134</a>]. However, nicotinic acetylcholine receptors can affect many other neurotransmitter systems (for example, nicotine can enhance current mediated by glutamate receptors in dopamine neurons of the rat ventral tegmentum [<a href="#rid135">135,136</a>]), and so it is not clear whether the cholinergic system is primarily disrupted in schizophrenia or the disruption is secondary to other pathological characteristics of the illness.</p><p class="headingAnchor" id="H3374168427"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117525.html" rel="external">"Society guideline links: Psychotic disorders"</a>.)</p><p class="headingAnchor" id="H1475992"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schizophrenia</strong> – Schizophrenia is among the most disabling and economically catastrophic medical disorders. Characteristic manifestations of schizophrenia typically include positive symptoms; disorganized speech; negative symptoms; and impairments in cognition. The illness is commonly associated with impaired social and occupational functioning. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Schizophrenia has a worldwide prevalence approaching 1 percent, with an incidence of approximately 1.5 new cases annually per 10,000 people. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Co-occurring conditions </strong>– Individuals with schizophrenia have higher rates of co-occurring depression, anxiety disorders, substance use disorders, and suicidal ideation and behavior compared to people without schizophrenia. (See <a class="local">'Co-occurring conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deficit schizophrenia </strong>– Approximately 15 to 20 percent of individuals with schizophrenia have the deficit form of schizophrenia, characterized by primary, enduring negative symptoms. (See <a class="local">'Deficit schizophrenia'</a> above and  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis", section on 'Negative symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Although the pathogenesis of the disorder is unknown, schizophrenia is likely a heterogeneous syndrome comprised of multiple diseases that present with similar signs and symptoms. The disorder appears to proceed from a complex interaction between genes and external/environmental factors. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>External factors</strong> – Obstetrical complications, perinatal infection, inflammation, cannabis use, tobacco use, immigration and childhood adversities appear to play a role in the development of schizophrenia. (See <a class="local">'External factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurodevelopment, neuropathology, and vulnerabilities </strong>– Schizophrenia is a neurodevelopmental disorder with neuropathological changes that may begin in utero. (See <a class="local">'Neurodevelopment, neuropathology, and vulnerabilities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurotransmitters</strong> – Several neurotransmitter systems are involved in the pathology of schizophrenia including dopamine, glutamate, gamma-aminobutyric acid, and acetylcholine. These represent the current best targets for pharmacologic intervention in the disorder. (See <a class="local">'Neurotransmitters'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Murray CJL, Lopez AD. The Global Burden of Disease, Harvard University Press, Cambridge, MA 1996. p.21.</li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</li><li><a class="nounderline abstract_t">McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30:67.</a></li><li><a class="nounderline abstract_t">Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010; 22:417.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual, Fourth Edition Text Revision (DSM-IV TR), American Psychiatric Publishing, Arlington 2000.</li><li><a class="nounderline abstract_t">Grossman LS, Harrow M, Rosen C, et al. Sex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recovery. Compr Psychiatry 2008; 49:523.</a></li><li><a class="nounderline abstract_t">Usall J, Ochoa S, Araya S, et al. Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample. Eur Psychiatry 2003; 18:282.</a></li><li><a class="nounderline abstract_t">Vassos E, Sham P, Kempton M, et al. The Maudsley environmental risk score for psychosis. Psychol Med 2020; 50:2213.</a></li><li><a class="nounderline abstract_t">Krabbendam L, van Os J. Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk. Schizophr Bull 2005; 31:795.</a></li><li><a class="nounderline abstract_t">Pedersen CB, Mortensen PB. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry 2001; 58:1039.</a></li><li><a class="nounderline abstract_t">Werbeloff N, Levine SZ, Rabinowitz J. Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15 years. Soc Psychiatry Psychiatr Epidemiol 2012; 47:303.</a></li><li><a class="nounderline abstract_t">Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychol Med 2011; 41:897.</a></li><li><a class="nounderline abstract_t">Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull 2006; 32:3.</a></li><li><a class="nounderline abstract_t">Miller B, Messias E, Miettunen J, et al. Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophr Bull 2011; 37:1039.</a></li><li><a class="nounderline abstract_t">Kong A, Frigge ML, Masson G, et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature 2012; 488:471.</a></li><li><a class="nounderline abstract_t">Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. Schizophr Bull 2016; 42:1262.</a></li><li><a class="nounderline abstract_t">Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry 2015; 2:718.</a></li><li><a class="nounderline abstract_t">Varese F, Smeets F, Drukker M, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull 2012; 38:661.</a></li><li><a class="nounderline abstract_t">Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005; 66:1122.</a></li><li><a class="nounderline abstract_t">Somaiya M, Grover S, Avasthi A, Chakrabarti S. Changes in cost of treating schizophrenia: comparison of two studies done a decade apart. Psychiatry Res 2014; 215:547.</a></li><li><a class="nounderline abstract_t">Nicholl D, Akhras KS, Diels J, Schadrack J. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010; 26:943.</a></li><li><a class="nounderline abstract_t">Feldman R, Bailey RA, Muller J, et al. Cost of schizophrenia in the Medicare program. Popul Health Manag 2014; 17:190.</a></li><li><a class="nounderline abstract_t">Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001; 58:165.</a></li><li><a class="nounderline abstract_t">Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res 1993; 47:47.</a></li><li><a class="nounderline abstract_t">Amador XF, Kirkpatrick B, Buchanan RW, et al. Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry 1999; 156:637.</a></li><li><a class="nounderline abstract_t">Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:578.</a></li><li><a class="nounderline abstract_t">Kirkpatrick B, Mitchell BD, DeLisi LE. Concordance of the deficit/nondeficit categorization in affected siblings. Schizophr Bull 2007; 33:282.</a></li><li><a class="nounderline abstract_t">Kirkpatrick B, Castle D, Murray RM, Carpenter WT Jr. Risk factors for the deficit syndrome of schizophrenia. Schizophr Bull 2000; 26:233.</a></li><li><a class="nounderline abstract_t">Dollfus S, Ribeyre JM, Petit M. Family history and deficit form in schizophrenia. Eur Psychiatry 1996; 11:260.</a></li><li><a class="nounderline abstract_t">Kirkpatrick B, Ross DE, Walsh D, et al. Family characteristics of deficit and nondeficit schizophrenia in the Roscommon Family Study. Schizophr Res 2000; 45:57.</a></li><li><a class="nounderline abstract_t">Ross DE, Kirkpatrick B, Karkowski LM, et al. Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. Am J Psychiatry 2000; 157:1071.</a></li><li><a class="nounderline abstract_t">Messias E, Kirkpatrick B, Bromet E, et al. Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry 2004; 61:985.</a></li><li><a class="nounderline abstract_t">Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994; 151:351.</a></li><li><a class="nounderline abstract_t">Kirkpatrick B, Amador XF, Flaum M, et al. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res 1996; 20:69.</a></li><li><a class="nounderline abstract_t">Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis 1994; 182:452.</a></li><li><a class="nounderline abstract_t">Fischer BA, Carpenter WT Jr. Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology 2009; 34:2081.</a></li><li><a class="nounderline abstract_t">Kringlen E. Twin studies in schizophrenia with special emphasis on concordance figures. Am J Med Genet 2000; 97:4.</a></li><li><a class="nounderline abstract_t">Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999; 56:162.</a></li><li><a class="nounderline abstract_t">Cannon TD, Kaprio J, Lönnqvist J, et al. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry 1998; 55:67.</a></li><li><a class="nounderline abstract_t">Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511:421.</a></li><li><a class="nounderline abstract_t">Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature 2016; 530:177.</a></li><li><a class="nounderline abstract_t">Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience 2013; 251:90.</a></li><li><a class="nounderline abstract_t">Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 2022; 604:502.</a></li><li><a class="nounderline abstract_t">Stefansson H, Rujescu D, Cichon S, et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008; 455:232.</a></li><li><a class="nounderline abstract_t">Smigielski L, Jagannath V, Rössler W, et al. Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings. Mol Psychiatry 2020; 25:1718.</a></li><li><a class="nounderline abstract_t">Lockwood L, Miller B, Youssef NA. Epigenetics and first-episode psychosis: A systematic review. Psychiatry Res 2022; 307:114325.</a></li><li><a class="nounderline abstract_t">Buka SL, Goldstein JM, Seidman LJ, Tsuang MT. Maternal recall of pregnancy history: accuracy and bias in schizophrenia research. Schizophr Bull 2000; 26:335.</a></li><li><a class="nounderline abstract_t">Walshe M, McDonald C, Boydell J, et al. Long-term maternal recall of obstetric complications in schizophrenia research. Psychiatry Res 2011; 187:335.</a></li><li><a class="nounderline abstract_t">Ursini G, Punzi G, Chen Q, et al. Convergence of placenta biology and genetic risk for schizophrenia. Nat Med 2018; 24:792.</a></li><li><a class="nounderline abstract_t">Susser E, Neugebauer R, Hoek HW, et al. Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry 1996; 53:25.</a></li><li><a class="nounderline abstract_t">St Clair D, Xu M, Wang P, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA 2005; 294:557.</a></li><li><a class="nounderline abstract_t">Xu MQ, Sun WS, Liu BX, et al. Prenatal malnutrition and adult schizophrenia: further evidence from the 1959-1961 Chinese famine. Schizophr Bull 2009; 35:568.</a></li><li><a class="nounderline abstract_t">Myhrman A, Rantakallio P, Isohanni M, et al. Unwantedness of a pregnancy and schizophrenia in the child. Br J Psychiatry 1996; 169:637.</a></li><li><a class="nounderline abstract_t">Huttunen MO, Niskanen P. Prenatal loss of father and psychiatric disorders. Arch Gen Psychiatry 1978; 35:429.</a></li><li><a class="nounderline abstract_t">Koenig JI, Elmer GI, Shepard PD, et al. Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. Behav Brain Res 2005; 156:251.</a></li><li><a class="nounderline abstract_t">Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167:261.</a></li><li><a class="nounderline abstract_t">Mortensen PB, Nørgaard-Pedersen B, Waltoft BL, et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry 2007; 61:688.</a></li><li><a class="nounderline abstract_t">Brown AS, Schaefer CA, Quesenberry CP Jr, et al. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry 2005; 162:767.</a></li><li><a class="nounderline abstract_t">Buka SL, Cannon TD, Torrey EF, et al. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry 2008; 63:809.</a></li><li><a class="nounderline abstract_t">Buka SL, Tsuang MT, Torrey EF, et al. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001; 58:1032.</a></li><li><a class="nounderline abstract_t">Brown AS, Schaefer CA, Quesenberry CP Jr, et al. No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? Am J Psychiatry 2006; 163:2178.</a></li><li><a class="nounderline abstract_t">Pedersen MG, Stevens H, Pedersen CB, et al. Toxoplasma infection and later development of schizophrenia in mothers. Am J Psychiatry 2011; 168:814.</a></li><li><a class="nounderline abstract_t">Dickerson F, Stallings C, Origoni A, et al. Antibodies to measles in individuals with recent onset psychosis. Schizophr Res 2010; 119:89.</a></li><li><a class="nounderline abstract_t">Blomström Å, Karlsson H, Svensson A, et al. Hospital admission with infection during childhood and risk for psychotic illness--a population-based cohort study. Schizophr Bull 2014; 40:1518.</a></li><li><a class="nounderline abstract_t">Nielsen PR, Benros ME, Mortensen PB. Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of Danish national registers. Schizophr Bull 2014; 40:1526.</a></li><li><a class="nounderline abstract_t">Weiser M, Werbeloff N, Levine A, et al. CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. Schizophr Res 2010; 124:231.</a></li><li><a class="nounderline abstract_t">Benros ME, Nielsen PR, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011; 168:1303.</a></li><li><a class="nounderline abstract_t">Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70:663.</a></li><li><a class="nounderline abstract_t">Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009; 63:257.</a></li><li><a class="nounderline abstract_t">Kato TA, Monji A, Mizoguchi Y, et al. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? Mini Rev Med Chem 2011; 11:565.</a></li><li><a class="nounderline abstract_t">Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011; 165:593.</a></li><li><a class="nounderline abstract_t">Eaton WW, Byrne M, Ewald H, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 2006; 163:521.</a></li><li><a class="nounderline abstract_t">Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr Res 1992; 6:181.</a></li><li><a class="nounderline abstract_t">Dickerson F, Stallings C, Origoni A, et al. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol Psychiatry 2010; 68:100.</a></li><li><a class="nounderline abstract_t">Samaroo D, Dickerson F, Kasarda DD, et al. Novel immune response to gluten in individuals with schizophrenia. Schizophr Res 2010; 118:248.</a></li><li><a class="nounderline abstract_t">Severance EG, Dickerson FB, Halling M, et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res 2010; 118:240.</a></li><li><a class="nounderline abstract_t">Severance EG, Lin J, Sampson HA, et al. Dietary antigens, epitope recognition, and immune complex formation in recent onset psychosis and long-term schizophrenia. Schizophr Res 2011; 126:43.</a></li><li><a class="nounderline abstract_t">Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2:1483.</a></li><li><a class="nounderline abstract_t">van Os J, Bak M, Hanssen M, et al. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156:319.</a></li><li><a class="nounderline abstract_t">Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011; 342:d738.</a></li><li><a class="nounderline abstract_t">McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; 67:440.</a></li><li><a class="nounderline abstract_t">Gage SH, Hickman M, Zammit S. Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biol Psychiatry 2016; 79:549.</a></li><li><a class="nounderline abstract_t">van Winkel R, Kuepper R. Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis. Annu Rev Clin Psychol 2014; 10:767.</a></li><li><a class="nounderline abstract_t">Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 2019; 6:427.</a></li><li><a class="nounderline abstract_t">Hjorthøj C, Posselt CM, Nordentoft M. Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark. JAMA Psychiatry 2021; 78:1013.</a></li><li><a class="nounderline abstract_t">Hjorthøj C, Compton W, Starzer M, et al. Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychol Med 2023; 53:7322.</a></li><li><a class="nounderline abstract_t">Leweke FM, Mueller JK, Lange B, Rohleder C. Therapeutic Potential of Cannabinoids in Psychosis. Biol Psychiatry 2016; 79:604.</a></li><li><a class="nounderline abstract_t">Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2013; 27:19.</a></li><li><a class="nounderline abstract_t">King M, Jones R, Petersen I, et al. Cigarette smoking as a risk factor for schizophrenia or all non-affective psychoses. Psychol Med 2021; 51:1373.</a></li><li><a class="nounderline abstract_t">Niemelä S, Sourander A, Surcel HM, et al. Prenatal Nicotine Exposure and Risk of Schizophrenia Among Offspring in a National Birth Cohort. Am J Psychiatry 2016; 173:799.</a></li><li><a class="nounderline abstract_t">Ferchiou A, Szöke A, Laguerre A, et al. Exploring the relationships between tobacco smoking and schizophrenia in first-degree relatives. Psychiatry Res 2012; 200:674.</a></li><li><a class="nounderline abstract_t">Selten JP, Hoek HW. Does misdiagnosis explain the schizophrenia epidemic among immigrants from developing countries to Western Europe? Soc Psychiatry Psychiatr Epidemiol 2008; 43:937.</a></li><li><a class="nounderline abstract_t">Youngmann R, Pugachova I, Zilber N. Patterns of psychiatric hospitalization among ethiopian and former soviet union immigrants and persons born in Israel. Psychiatr Serv 2009; 60:1656.</a></li><li><a class="nounderline abstract_t">Coid JW, Kirkbride JB, Barker D, et al. Raised incidence rates of all psychoses among migrant groups: findings from the East London first episode psychosis study. Arch Gen Psychiatry 2008; 65:1250.</a></li><li><a class="nounderline abstract_t">McGrath JJ, Eyles DW, Pedersen CB, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry 2010; 67:889.</a></li><li><a class="nounderline abstract_t">Weinberger DR. On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Neuropsychopharmacology 1996; 14:1S.</a></li><li><a class="nounderline abstract_t">Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003; 361:281.</a></li><li><a class="nounderline abstract_t">Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J Psychiatr Res 1994; 28:239.</a></li><li><a class="nounderline abstract_t">Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44:660.</a></li><li><a class="nounderline abstract_t">Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res 1982-1983; 17:319.</a></li><li><a class="nounderline abstract_t">Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr 2018; 23:187.</a></li><li><a class="nounderline abstract_t">Townsend L, Pillinger T, Selvaggi P, et al. Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of 18FDG-PET studies in schizophrenia. Psychol Med 2023; 53:4880.</a></li><li><a class="nounderline abstract_t">Benjamin KJM, Chen Q, Jaffe AE, et al. Analysis of the caudate nucleus transcriptome in individuals with schizophrenia highlights effects of antipsychotics and new risk genes. Nat Neurosci 2022; 25:1559.</a></li><li class="breakAll">Fischer BA, Kirkpatrick B, Carpenter WT. The neurobiology of negative symptoms and the deficit syndrome. In: The Handbook of Neurochemistry and Molecular Neurobiology: Schizophrenia, 3rd ed, Javitt DC, Kantrowitz JT (Eds), Springer Science and Business Media LLC, New York 2009. Vol 27, p.507.</li><li><a class="nounderline abstract_t">Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004; 174:3.</a></li><li><a class="nounderline abstract_t">Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301.</a></li><li><a class="nounderline abstract_t">Lahti AC, Weiler MA, Tamara Michaelidis BA, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25:455.</a></li><li><a class="nounderline abstract_t">Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999; 20:106.</a></li><li><a class="nounderline abstract_t">Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199.</a></li><li><a class="nounderline abstract_t">Geddes AE, Huang XF, Newell KA. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:896.</a></li><li><a class="nounderline abstract_t">Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50:521.</a></li><li><a class="nounderline abstract_t">Erhardt S, Schwieler L, Nilsson L, et al. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007; 92:203.</a></li><li><a class="nounderline abstract_t">Bojesen KB, Ebdrup BH, Jessen K, et al. Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis. Psychol Med 2020; 50:2182.</a></li><li><a class="nounderline abstract_t">Kiemes A, Davies C, Kempton MJ, et al. GABA, Glutamate and Neural Activity: A Systematic Review With Meta-Analysis of Multimodal 1H-MRS-fMRI Studies. Front Psychiatry 2021; 12:644315.</a></li><li><a class="nounderline abstract_t">Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164:1593.</a></li><li><a class="nounderline abstract_t">Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13:1102.</a></li><li><a class="nounderline abstract_t">Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003; 23:6315.</a></li><li><a class="nounderline abstract_t">Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000; 57:1061.</a></li><li><a class="nounderline abstract_t">Pierri JN, Chaudry AS, Woo TU, Lewis DA. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 1999; 156:1709.</a></li><li><a class="nounderline abstract_t">Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A 1998; 95:5341.</a></li><li><a class="nounderline abstract_t">Volk D, Austin M, Pierri J, et al. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 2001; 158:256.</a></li><li><a class="nounderline abstract_t">Volk DW, Pierri JN, Fritschy JM, et al. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 2002; 12:1063.</a></li><li><a class="nounderline abstract_t">Kinon BJ, Zhang L, Millen BA, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011; 31:349.</a></li><li><a class="nounderline abstract_t">Uçok A, Polat A, Bozkurt O, Meteris H. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 2004; 58:434.</a></li><li><a class="nounderline abstract_t">de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76:135.</a></li><li><a class="nounderline abstract_t">Williams JM, Gandhi KK, Lu SE, et al. Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. Nicotine Tob Res 2010; 12:855.</a></li><li><a class="nounderline abstract_t">Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997; 42:1.</a></li><li><a class="nounderline abstract_t">Avila MT, Sherr JD, Hong E, et al. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 2003; 28:2184.</a></li><li><a class="nounderline abstract_t">Olincy A, Johnson LL, Ross RG. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 2003; 117:223.</a></li><li><a class="nounderline abstract_t">Sherr JD, Myers C, Avila MT, et al. The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 2002; 52:721.</a></li><li><a class="nounderline abstract_t">Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993; 150:1856.</a></li><li><a class="nounderline abstract_t">Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63:630.</a></li><li><a class="nounderline abstract_t">Hong LE, Schroeder M, Ross TJ, et al. Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull 2011; 37:416.</a></li><li><a class="nounderline abstract_t">Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165:1040.</a></li><li><a class="nounderline abstract_t">Mao D, Gallagher K, McGehee DS. Nicotine potentiation of excitatory inputs to ventral tegmental area dopamine neurons. J Neurosci 2011; 31:6710.</a></li><li><a class="nounderline abstract_t">Jin Y, Yang K, Wang H, Wu J. Exposure of nicotine to ventral tegmental area slices induces glutamatergic synaptic plasticity on dopamine neurons. Synapse 2011; 65:332.</a></li></ol></div><div id="topicVersionRevision">Topic 14804 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Murray CJL, Lopez AD. The Global Burden of Disease, Harvard University Press, Cambridge, MA 1996. p.21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480098" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Schizophrenia: a concise overview of incidence, prevalence, and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21047156" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Sex differences in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21047156" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sex differences in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18970899" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14611922" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31535606" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The Maudsley environmental risk score for psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150958" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11695950" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21286683" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20663257" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16306181" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of obstetric events in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185538" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Meta-analysis of paternal age and schizophrenia risk in male versus female offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914163" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Rate of de novo mutations and the importance of father's age to disease risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884547" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26249303" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Does tobacco use cause psychosis? Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461484" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16187769" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The economic burden of schizophrenia in the United States in 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24495571" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Changes in cost of treating schizophrenia: comparison of two studies done a decade apart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20163295" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24156665" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cost of schizophrenia in the Medicare program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11177118" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A separate disease within the syndrome of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8516416" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Case identification and stability of the deficit syndrome of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10200748" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Stability of the diagnosis of deficit syndrome in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3358462" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Deficit and nondeficit forms of schizophrenia: the concept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Concordance of the deficit/nondeficit categorization in affected siblings</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755684" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors for the deficit syndrome of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19698462" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Family history and deficit form in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10978873" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Family characteristics of deficit and nondeficit schizophrenia in the Roscommon Family Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10873913" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466671" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Summer birth and deficit schizophrenia: a pooled analysis from 6 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7906493" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794495" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040655" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Depressive symptoms and the deficit syndrome of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19295511" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Will the Kraepelinian dichotomy survive DSM-V?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10813799" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Twin studies in schizophrenia with special emphasis on concordance figures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025441" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Heritability estimates for psychotic disorders: the Maudsley twin psychosis series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435762" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25056061" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Biological insights from 108 schizophrenia-associated genetic loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26814963" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Schizophrenia risk from complex variation of complement component 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22546337" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Dendritic spine pathology in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35396580" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mapping genomic loci implicates genes and synaptic biology in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668039" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Large recurrent microdeletions associated with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31907379" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34896847" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Epigenetics and first-episode psychosis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10885635" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Maternal recall of pregnancy history: accuracy and bias in schizophrenia research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324530" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term maternal recall of obstetric complications in schizophrenia research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29808008" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Convergence of placenta biology and genetic risk for schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8540774" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Schizophrenia after prenatal famine. Further evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16077049" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19155344" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prenatal malnutrition and adult schizophrenia: further evidence from the 1959-1961 Chinese famine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8932895" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Unwantedness of a pregnancy and schizophrenia in the child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/727894" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prenatal loss of father and psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15582111" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20123911" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prenatal infection and schizophrenia: a review of epidemiologic and translational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16920078" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800151" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981263" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11695949" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Maternal infections and subsequent psychosis among offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17151171" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536690" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Toxoplasma infection and later development of schizophrenia in mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051313" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Antibodies to measles in individuals with recent onset psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366719" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hospital admission with infection during childhood and risk for psychotic illness--a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24379444" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of Danish national registers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846826" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : CNS infection in childhood does not confer risk for later schizophrenia: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22193673" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21641581" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19579286" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cytokines and schizophrenia: Microglia hypothesis of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699487" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21517800" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16513876" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Association of schizophrenia and autoimmune diseases: linkage of Danish national registers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571312" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Schizophrenia and rheumatoid arthritis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20471632" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19748229" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Novel immune response to gluten in individuals with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20071146" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21211944" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Dietary antigens, epitope recognition, and immune complex formation in recent onset psychosis and long-term schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2892048" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181101" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cannabis use and psychosis: a longitudinal population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21363868" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194820" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26386480" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Association Between Cannabis and Psychosis: Epidemiologic Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24471373" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Epidemiological, neurobiological, and genetic clues to the mechanisms linking cannabis use to risk for nonaffective psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30902669" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34287621" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37140715" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Association between cannabis use disorder and schizophrenia stronger in young males than in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26852073" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Therapeutic Potential of Cannabinoids in Psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042808" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32148211" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cigarette smoking as a risk factor for schizophrenia or all non-affective psychoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27216261" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prenatal Nicotine Exposure and Risk of Schizophrenia Among Offspring in a National Birth Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22939230" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Exploring the relationships between tobacco smoking and schizophrenia in first-degree relatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18587677" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Does misdiagnosis explain the schizophrenia epidemic among immigrants from developing countries to Western Europe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952157" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Patterns of psychiatric hospitalization among ethiopian and former soviet union immigrants and persons born in Israel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981336" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Raised incidence rates of all psychoses among migrant groups: findings from the East London first episode psychosis study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20819982" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8866738" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12559861" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7932285" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3606332" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Implications of normal brain development for the pathogenesis of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7187776" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29954475" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35730361" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of 18FDG-PET studies in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36319771" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Analysis of the caudate nucleus transcriptome in individuals with schizophrenia highlights effects of antipsychotics and new risk genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36319771" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Analysis of the caudate nucleus transcriptome in individuals with schizophrenia highlights effects of antipsychotics and new risk genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15118803" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1654746" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Recent advances in the phencyclidine model of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11557159" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effects of ketamine in normal and schizophrenic volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9885791" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8122957" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371516" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600105" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Increased cortical kynurenate content in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573079" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The kynurenic acid hypothesis of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31524118" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33762983" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : GABA, Glutamate and Neural Activity: A Systematic Review With Meta-Analysis of Multimodal 1H-MRS-fMRI Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898352" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17767166" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867516" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074872" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10553733" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9560277" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11156808" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12217970" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508856" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15298658" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Cigarette smoking among patients with schizophrenia and bipolar disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15949648" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584771" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193735" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12968127" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686365" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12372663" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : The effects of nicotine on specific eye tracking measures in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8238642" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Normalization of auditory physiology by cigarette smoking in schizophrenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754836" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19713300" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381905" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Initial phase 2 trial of a nicotinic agonist in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543600" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Nicotine potentiation of excitatory inputs to ventral tegmental area dopamine neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20730803" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Exposure of nicotine to ventral tegmental area slices induces glutamatergic synaptic plasticity on dopamine neurons.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
